Shanghai Henlius Biotech

This phase II trial tests two drugs—HLX43 and serplulimab—given before surgery to people with stage II-IIIB non-small cell lung cancer. The goal is to see if the combination can reduce tumor size, making surgery more effective. About 60 participants will be enrolled to evaluate s…

This study tests two experimental drugs, HLX43 and HLX07, alone or together, against a standard chemotherapy (docetaxel) in people with advanced squamous non-small cell lung cancer whose first treatment stopped working. About 706 adults worldwide will take part. The goal is to se…

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests if a new drug, HLX15-SC, works as well as the approved drug DARZALEX FASPRO® for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 258 adults will receive either the new drug or the approved one, along with standard medica…

This phase 2 trial tests a drug called HLX43 in 102 people with advanced esophageal cancer that did not respond to or could not tolerate standard first-line therapy. HLX43 is an antibody-drug conjugate designed to deliver a chemotherapy agent directly to cancer cells. The study a…

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people who have had surgery for non-small cell lung cancer, melanoma, or kidney cancer. The goal is to see how the drug moves through the body, how safe it is, and how well it works …

This early-phase study tests a new drug called HLX3901 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 138 adults aged 18 to 75 will take part.

This study tests a drug called HLX43 in 190 people with advanced cervical or ovarian cancer that came back or spread after initial treatment. HLX43 is designed to deliver a toxin directly to cancer cells by targeting a protein called PD-L1. The goal is to see if it can shrink tum…

This study tests whether combining two experimental drugs (HLX22 and HLX87) works better as a first treatment for HER2-positive breast cancer that has returned or spread. About 706 adults with advanced or metastatic breast cancer will participate. The main goals are to see how ma…

This study tests a new drug called HLX13, which is a biosimilar (a very similar copy) of the approved immunotherapy YERVOY, in people with advanced liver cancer that cannot be removed by surgery. The trial will compare HLX13 to the original YERVOY, both given alongside another im…

This study tests a new drug called HLX43 in people whose head and neck cancer has returned or spread to other parts of the body. The drug works by targeting a protein (PD-L1) on cancer cells to help the immune system attack them. About 167 adults aged 18 to 75 will take part to s…

This early-phase study tests HLX37, a new drug that targets two cancer growth pathways (PD-L1 and VEGF) at once, in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Up to 254 par…

This Phase 3 trial tests whether adding an experimental antibody (HLX22) to standard treatment (trastuzumab plus chemotherapy) works better for people with advanced HER2-positive stomach or gastroesophageal junction cancer. About 550 participants will be randomly assigned to rece…

This phase 2 trial tests HLX43, a drug that targets a protein called PD-L1 on cancer cells and delivers a toxin to kill them. It is for people with recurrent or metastatic nasopharyngeal carcinoma who have failed or cannot tolerate second-line therapy. About 70 participants will …

This Phase 2 trial is testing an experimental drug called HLX43 in 60 people with advanced gastric or gastroesophageal junction cancer. HLX43 is a targeted therapy that delivers a potent chemotherapy agent directly to cancer cells. The study aims to find the best dose and see how…

This study tests a new drug called HLX43 in 60 people with advanced colorectal cancer that has stopped responding to standard treatments. The drug is designed to attach to a protein on cancer cells and deliver a toxin to kill them. The main goal is to find the right dose and see …

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) for people with active kidney inflammation called glomerulonephritis. About 24 adults with membranous nephropathy or lupus-related kidney disease will receive either the new drug or a pla…

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced or metastatic solid tumors, including non-small cell lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults aged 18 to 75 who hav…

This early-stage trial tests HLX42, a drug that targets a protein called EGFR found on some cancer cells. The drug delivers a powerful chemotherapy directly to the tumor. The study involves about 100 adults with advanced solid tumors, including non-small cell lung cancer, who hav…